Every 8-K that DROR ORTHO-DESIGN INC (DROR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DROR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DROR filings page.
Dror Ortho-Design, Inc. (DROR) reported that stockholders approved all proposals submitted at its September 23, 2026 special meeting. As of August 27, 2026, 976,997,116 common shares were outstanding and entitled to vote. The company also had 5,847,937 Series A Convertible Preferred shares outstanding, entitled to cast an aggregate 584,793,700 votes, subject to beneficial ownership limitations.
The first displayed vote tally recorded 707,862,992.08 votes for and 1,451,900 against; the second recorded 709,192,992.08 votes for and 121,900 against. The results are final, and no other matters were considered or voted on.
Dror Ortho-Design, Inc. (DROR) entered into a Securities Purchase Agreement for a private placement of unsecured debentures with institutional purchasers. The company issued $275,000 aggregate principal amount of zero-coupon debentures due October 19, 2026, in a transaction exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D.
If Dror completes a public equity offering before maturity, the then-outstanding debentures automatically convert into common stock at the public offering per-share price, and those conversion shares receive the same terms and accompanying warrants as public offering investors. Purchasers are also entitled, upon such a public offering, to additional warrants with coverage formulas based on 100%–150% of the debenture conversion shares and hypothetical public-offering warrant allocations. Any debenture conversion or warrant exercise is limited by a 9.99% beneficial ownership cap per holder, adjustable with 61 days’ notice. Warrants, if issued, will be exercisable immediately at the public offering price, have a five-year term, include customary anti-dilution and price-based adjustments, and will not be listed on a national exchange.
Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement of 0% interest debentures with an aggregate principal amount of $275,000, due on June 28, 2026. The debentures may automatically convert into common stock at the per-share price of any future public offering.
If a public offering occurs, investors are also entitled to receive warrants to buy common stock, with the number of warrants tied to the potential conversion shares and the size of the public offering allocation. Any warrants issued will be exercisable immediately at the public offering price and will expire five years after issuance. Both the debentures and any warrants carry ownership caps that generally limit a holder to beneficial ownership below 4.99%, with an option to increase this cap to 9.99% on 61 days’ notice. The transaction was completed as an unregistered offering under Section 4(a)(2) and Regulation D.
Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement of 0% senior debentures with an aggregate principal amount of $200,000, due April 27, 2026. The transaction closed the same day for a $200,000 purchase price.
If the company completes a public offering before maturity, the outstanding debentures automatically convert into common stock at the public offering share price, with resulting shares carrying the same terms as offering shares. Investors may also receive multi-year warrants with exercise prices tied to the public offering price, subject to formulas based on whether the debentures remain outstanding.
Both debenture conversions and warrant exercises are limited by a 9.99% beneficial ownership cap per holder. The securities were sold in a private placement to accredited investors under Section 4(a)(2) and Regulation D exemptions.
Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement of Debentures with an aggregate principal amount of $250,000, which closed on December 30, 2025. The Debentures bear 0% interest and mature on February 28, 2026, with holders able to extend maturity in 60-day increments. If the company completes a public offering before maturity, the outstanding principal will automatically convert into common stock at the same per-share price used in that offering, and the resulting shares will carry the same terms as those sold in the offering.
Subject to completion of a public offering, investors are also entitled to receive Warrants to buy common stock at the public offering price, expiring five years from issuance, with customary anti-dilution and price-based adjustments. Both the Debentures and any Warrants include a 9.99% beneficial ownership cap, limiting how much equity any holder can acquire through conversion or exercise. The transaction was conducted as an unregistered offering under Section 4(a)(2) and Regulation D, with all purchasers represented as accredited investors.
Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement of 0% debentures with an aggregate principal amount of $200,000, maturing on February 2, 2026. If the company completes a public offering before maturity, the outstanding debentures will automatically convert into common shares at the public offering share price, with those shares carrying the same terms and any accompanying warrants and registration rights as in the offering.
Subject to the completion of that public offering, investors are also entitled to warrants for additional common shares, with quantities tied to the number of debenture conversion shares and a defined “warrant subscription amount.” Any warrants issued will be immediately exercisable at the public offering price and will expire five years after issuance. Both debenture conversions and warrant exercises are capped so that a holder cannot beneficially own more than 9.99% of outstanding common stock. The transaction was conducted as an unregistered private placement under Section 4(a)(2) and Regulation D.